Samtani MN - Search Results

1

Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).

Pina LM, Dong X, Zhang L, Samtani MN, Michelson AD, Justino H, Bonnet D, Harris KC, Jefferies J, McCrindle BW, Li JS. Pina LM, et al. Among authors: samtani mn. Am Heart J. 2019 Jul;213:97-104. doi: 10.1016/j.ahj.2019.04.009. Epub 2019 May 1. Am Heart J. 2019. PMID: 31132584

2

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G. Coppola D, et al. Among authors: samtani mn. BMC Psychiatry. 2012 Mar 28;12:26. doi: 10.1186/1471-244X-12-26. BMC Psychiatry. 2012. PMID: 22455454 Free PMC article. Clinical Trial.

3

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.

Ravenstijn P, Remmerie B, Savitz A, Samtani MN, Nuamah I, Chang CT, De Meulder M, Hough D, Gopal S. Ravenstijn P, et al. Among authors: samtani mn. J Clin Pharmacol. 2016 Mar;56(3):330-9. doi: 10.1002/jcph.597. Epub 2015 Oct 5. J Clin Pharmacol. 2016. PMID: 26189570 Clinical Trial.

4

Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.

Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Samtani MN, et al. CNS Drugs. 2011 Oct 1;25(10):829-45. doi: 10.2165/11591690-000000000-00000. CNS Drugs. 2011. PMID: 21936586 Review.

5

Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.

Russu A, Savitz A, Mathews M, Gopal S, Feng Y, Samtani MN. Russu A, et al. Among authors: samtani mn. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):567-574. doi: 10.1097/JCP.0000000000001137. J Clin Psychopharmacol. 2019. PMID: 31688450 Clinical Trial.

6

A novel subject synchronization clinical trial design for Alzheimer's disease.

Schultz T, Yang E, Farnum M, Lobanov V, Verbeeck R, Raghavan N, Samtani MN, Novak G, Shi Y, Narayan V, DiBernardo A. Schultz T, et al. Among authors: samtani mn. J Alzheimers Dis. 2012;31(3):507-16. doi: 10.3233/JAD-2012-120286. J Alzheimers Dis. 2012. PMID: 22614878 Review.

7

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.

Gopal S, Vermeulen A, Nandy P, Ravenstijn P, Nuamah I, Buron Vidal JA, Berwaerts J, Savitz A, Hough D, Samtani MN. Gopal S, et al. Among authors: samtani mn. Curr Med Res Opin. 2015 Nov;31(11):2043-54. doi: 10.1185/03007995.2015.1085849. Epub 2015 Oct 2. Curr Med Res Opin. 2015. PMID: 26306819

8

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose.

Samtani MN, Nuamah I, Gopal S, Remmerie B, Kern Sliwa J, Alphs L. Samtani MN, et al. Neuropsychiatr Dis Treat. 2013;9:721-30. doi: 10.2147/NDT.S40836. Epub 2013 May 20. Neuropsychiatr Dis Treat. 2013. PMID: 23723704 Free PMC article.

9

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.

Samtani MN, Nandy P, Ravenstijn P, Remmerie B, Vermeulen A, Russu A, D'hoore P, Baum EZ, Savitz A, Gopal S, Hough D. Samtani MN, et al. Br J Clin Pharmacol. 2016 Nov;82(5):1364-1370. doi: 10.1111/bcp.13050. Epub 2016 Jul 24. Br J Clin Pharmacol. 2016. PMID: 27333588 Free PMC article. Clinical Trial.

10

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.

Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A. Magnusson MO, et al. Among authors: samtani mn. CNS Drugs. 2017 Apr;31(4):273-288. doi: 10.1007/s40263-017-0416-1. CNS Drugs. 2017. PMID: 28258365 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page